$THOR News
Last published 4mo ago
- 4mo agoTHORThornburg Extends Income Builder Franchise with Launch of THOR ETFPR NewswireThornburg Investment Management ("Thornburg"), a global investment firm with $60 billion in assets1, today announced the launch of the Thornburg...
- 6y agoTHORSanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of SynthorxGlobeNewswireHart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx Paris – January 20, 2020 - Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust...
- 6y agoKEMARQLMRKTHOR+1Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the FirmPR NewswireMoore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the...
- 6y agoTHORSanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 BillionGlobeNewswireSanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion Proprietary immuno-oncology (IO) platform synergistic with Sanofi’s existing therapeutic platforms Lead...
- 7y agoTHORSynthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual MeetingGlobeNewswireSAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
- 7y agoTHORSynthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewswireSAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...